| abstract |
The present invention relates to quinoline and quinoxaline compounds that inhibit platelet growth factor tyrosine kinase and / or p56 tyrosine kinase activity, to pharmaceutical compositions containing these compounds, and to the use of these compounds for treating a patient suffering from (or subject to) disorders and conditions including cell differentiation, proliferation, extracellular matrix production or mediator release and / or activation and proliferation of T cells. |